Kurokawa Shunya, Tomizawa Yoshihiro, Miyaho Katsuma, Ishii Daiki, Takamiya Akihiro, Ishii Chiharu, Sanada Kenji, Fukuda Shinji, Mimura Masaru, Kishimoto Taishiro
Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Division of Pharmacotherapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan.
J Psychiatr Res. 2021 Aug;140:45-52. doi: 10.1016/j.jpsychires.2021.05.009. Epub 2021 May 8.
There is growing evidence regarding the connection between alterations in gut microbiota and their metabolites in patients with depressive disorders, suggesting a potential role in pathophysiology. Our study aimed to investigate the relationship between microbial, metabolomic features and the course of treatment for depression in a real-world clinical setting.
Patients diagnosed with depressive disorders were recruited, and their stool was collected at three time points during their depression treatments. Patients were divided into three groups: non-responders, responders, and stable remitters. Gut microbiomes were analyzed using 16S rRNA gene sequencing, and gut metabolomes were analyzed by a mass spectrometry approach. Microbiomes/metabolomes were compared between groups cross-sectionally and longitudinally.
A total of 33 patients were recruited and divided into non-responders (n = 16), responders (n = 11), and stable remitters (n = 6). Non-responders presented lower alpha diversity in the Phylogenic Diversity index compared to responders during the treatment course (p = 0.003). Non-responders presented increased estimated glutamate synthesis functions by the microbiota compared to responders and stable remitters (p = 0.035). There were no specific microbiota or metabolome that differentiated the three groups.
Small sample size with no healthy controls.
Our results indicate that both cross-sectional microbial features and longitudinal microbial transitions are different depending on the treatment course of depression. Controlled studies, as well as animal studies, are needed in the future to elucidate the causal relationship between microbiota and depression.
越来越多的证据表明,抑郁症患者肠道微生物群及其代谢产物的改变之间存在联系,这表明其在病理生理学中可能发挥作用。我们的研究旨在调查现实临床环境中微生物、代谢组学特征与抑郁症治疗过程之间的关系。
招募被诊断为抑郁症的患者,并在其抑郁症治疗期间的三个时间点收集粪便。患者分为三组:无反应者、反应者和稳定缓解者。使用16S rRNA基因测序分析肠道微生物群,采用质谱方法分析肠道代谢组。对各组之间的微生物群/代谢组进行横断面和纵向比较。
共招募了33名患者,分为无反应者(n = 16)、反应者(n = 11)和稳定缓解者(n = 6)。在治疗过程中,无反应者在系统发生多样性指数中的α多样性低于反应者(p = 0.003)。与反应者和稳定缓解者相比,无反应者的微生物群估计谷氨酸合成功能增加(p = 0.035)。没有特定的微生物群或代谢组能够区分这三组。
样本量小且无健康对照。
我们的结果表明,根据抑郁症的治疗过程,横断面微生物特征和纵向微生物转变均有所不同。未来需要进行对照研究以及动物研究,以阐明微生物群与抑郁症之间的因果关系。